{"id":12471,"date":"2025-05-14T09:26:42","date_gmt":"2025-05-14T13:26:42","guid":{"rendered":"https:\/\/www.rigicon.com\/glossary-term\/alpha-blockers\/"},"modified":"2026-10-06T16:21:24","modified_gmt":"2026-10-06T20:21:24","slug":"bloqueadores-alfa-pt-br","status":"publish","type":"glossary-term","link":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","title":{"rendered":"Bloqueadores Alfa"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"","protected":false},"featured_media":0,"template":"","glossary-category":[114],"glossary-product":[104,105],"class_list":["post-12471","glossary-term","type-glossary-term","status-publish","hentry","glossary-category-urological-agents","glossary-product-infla10-pulse-ipp-series","glossary-product-rigi10-malleable-penile-prosthesis"],"acf":{"gt-definition":"<p>Os alfabloqueadores, tamb\u00e9m conhecidos como antagonistas alfa-adren\u00e9rgicos, s\u00e3o uma classe de medicamentos que atuam bloqueando os receptores alfa-adren\u00e9rgicos (receptores alfa) do sistema nervoso simp\u00e1tico. Essa a\u00e7\u00e3o impede que catecolaminas como a noradrenalina e a adrenalina se liguem a esses receptores, gerando diversos efeitos fisiol\u00f3gicos. Sua finalidade principal \u00e9 relaxar determinados m\u00fasculos e ajudar os pequenos vasos sangu\u00edneos a permanecerem abertos. Ao bloquear a a\u00e7\u00e3o dos nervos do sistema nervoso simp\u00e1tico, eles podem melhorar o fluxo sangu\u00edneo e reduzir a press\u00e3o arterial. Tamb\u00e9m s\u00e3o usados para relaxar o t\u00f4nus muscular da pr\u00f3stata e do colo vesical, melhorando assim o fluxo urin\u00e1rio em condi\u00e7\u00f5es como a hiperplasia prost\u00e1tica benigna (HPB). Os alfabloqueadores s\u00e3o classificados, de forma geral, em alfabloqueadores n\u00e3o seletivos (que bloqueiam os receptores alfa-1 e alfa-2) e alfabloqueadores seletivos (que atuam principalmente sobre os receptores alfa-1 ou alfa-2). Os bloqueadores alfa-1 seletivos s\u00e3o comumente usados na hipertens\u00e3o e na HPB, enquanto os alfabloqueadores n\u00e3o seletivos t\u00eam usos mais especializados, como no manejo do feocromocitoma. O mecanismo espec\u00edfico envolve a modula\u00e7\u00e3o do t\u00f4nus vascular e da libera\u00e7\u00e3o de noradrenalina, levando \u00e0 vasodilata\u00e7\u00e3o e ao relaxamento da musculatura lisa, dependendo do subtipo e da localiza\u00e7\u00e3o do receptor.\u207d\u00b9\u207e\u207d\u00b9\u2075\u207e<\/p>","gt-synonyms":"Antagonistas alfa-adren\u00e9rgicos, antagonistas dos receptores alfa-adren\u00e9rgicos, bloqueadores alfa, agentes bloqueadores alfa-adren\u00e9rgicos","gt-citation":"[1] Pacak K. Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab. 2007 Nov;92(11):4069-79. doi: 10.1210\/jc.2007-1720. Epub 2007 Sep 11. PMID: 17848402.\r\n\r\n[2] Ramachandran R, Rewari V. Current perioperative management of pheochromocytomas. Indian J Urol. 2017 Jan-Mar;33(1):19-25. doi: 10.4103\/0970-1591.194781. PMID: 28197025; PMCID: PMC5264186.\r\n\r\n[3] Richards JR, Hollander JE, Ramoska EA, Fareed FN, Sand IC, Izquierdo G\u00f3mez MM, Lange RA. \u03b2-Blockers, Cocaine, and the Unopposed \u03b1-Stimulation Phenomenon. J Cardiovasc Pharmacol Ther. 2017 May;22(3):239-249. doi: 10.1177\/1074248416681644. Epub 2016 Dec 14. PMID: 28399647.\r\n\r\n[4] Page RL, O'Bryant CL, Cheng D, Dow TJ, Ky B, Stein CM, Spencer AP, Trupp RJ, Lindenfeld J., American Heart Association Clinical Pharmacology and Heart Failure and Transplantation Committees of the Council on Clinical Cardiology; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular and Stroke Nursing; and Council on Quality of Care and Outcomes Research. Drugs That May Cause or Exacerbate Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2016 Aug 9;134(6):e32-69. doi: 10.1161\/CIR.0000000000000426. Erratum in: Circulation. 2016 Sep 20;134(12):e261. Erratum in: Circulation. 2017 Jan 31;135(5):e20. PMID: 27400984.\r\n\r\n[5] Thadchanamoorthy V, Dayaratna T. Phentolamine. StatPearls Publishing; 2024 Jan. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564363\/\r\n\r\n[6] McMahon CG. Current diagnosis and management of erectile dysfunction. Med J Aust. 2019 Jun;210(10):469-476. doi: 10.5694\/mja2.50167. Epub 2019 May 17. PMID: 31099420.\r\n\r\n[7] Coombs PG, Heck M, Guhring P, Narus J, Mulhall JP. A review of outcomes of an intracavernosal injection therapy programme. BJU Int. 2012 Dec;110(11):1787-91. doi: 10.1111\/j.1464-410X.2012.11080.x. Epub 2012 May 7. PMID: 22564343.\r\n\r\n[8] Duncan C, Omran GJ, Teh J, Davis NF, Bolton DM, Lawrentschuk N. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019 Jun;37(6):1007-1014. doi: 10.1007\/s00345-019-02727-5. Epub 2019 Mar 20. PMID: 30895359.\r\n\r\n[9] Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ., National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001\/jama.289.19.2560. Erratum in: JAMA. 2003 Jul 9;290(2):197. PMID: 12748199.\r\n\r\n[10] AUA Guideline on Management of Benign Prostatic Hyperplasia (BPH). American Urological Association. Updated 2023. Available from: https:\/\/www.auanet.org\/guidelines-and-quality\/guidelines\/benign-prostatic-hyperplasia-(bph -guideline\r\n\r\n[11] Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol. 1998 Feb;159(2):433-6. doi: 10.1016\/s0022-5347(01)63942-9. PMID: 9649257.\r\n\r\n[12] Tam SW, Worcel M, Wyllie M. Yohimbine: a clinical review. Pharmacol Ther. 2001 Sep;91(3):215-43. doi: 10.1016\/s0163-7258(01)00156-5. PMID: 11744068.\r\n\r\n[13] Ostojic SM. Yohimbine: the effects on body composition and exercise performance in soccer players. Res Sports Med. 2006 Oct-Dec;14(4):289-99. doi: 10.1080\/15438620600987106. PMID: 17214405.\r\n\r\n[14] Morales A. Yohimbine in erectile dysfunction: the facts. Int J Impot Res. 2000 Mar;12 Suppl 1:S70-4. doi: 10.1038\/sj.ijir.3900508. PMID: 10845767.\r\n\r\n[15] Katzung BG, Masters SB, Trevor AJ. Basic & Clinical Pharmacology. 12th ed. McGraw-Hill Medical; 2012.\r\n\r\n[17] Lepor H. Alpha-blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. PMID: 18231614; PMCID: PMC2213889.\r\n\r\n[18] Zhang HL, Huang ZG, Qiu Y, Cheng X, Zou XQ, Liu TT. Tamsulosin for treatment of lower urinary tract symptoms in women: a systematic review and meta-analysis. Int J Impot Res. 2017;29(4):148-156. doi:10.1038\/ijir.2017.12. PMID: 28424499.\n\r\n[19] Seitz C, Liatsikos E, Porpiglia F, Tiselius HG, Zwergel U. Medical therapy to facilitate the passage of stones: what is the evidence? Eur Urol. 2009 Sep;56(3):455-71. doi: 10.1016\/j.eururo.2009.06.012. Epub 2009 Jun 17. PMID: 19556043.\r\n\r\n[20] Hollingsworth JM, Canales BK, Rogers MA, Sukumar S, Yan P, Kuntz GM, Dahm P. Alpha blockers for treatment of ureteric stones: systematic review and meta-analysis. BMJ. 2016 Dec 1;355:i6112. doi: 10.1136\/bmj.i6112. PMID: 27908918; PMCID: PMC5131734.\r\n\r\n[21] Campschroer T, Zhu Y, Duijvesz D, Grobbee DE, Lock MT. Alpha-blockers as medical expulsive therapy for ureteral stones. Cochrane Database Syst Rev. 2018 Apr 11;4(4):CD008509. doi: 10.1002\/14651858.CD008509.pub3. PMID: 29637541; PMCID: PMC6494465.\r\n\r\n[22] Pickard R, Starr K, MacLennan G, Lam T, Thomas R, Burr J, Norrie J, McPherson G, McDonald A, Anson K, N'Dow J, Burgess N, Clark T, Kilonzo M, Gillies K, Boachie C, Erasmus P, McClinton S, Goodman C., SUSPEND Study Group. Medical expulsive therapy in adults with ureteric colic: a multicentre, randomised, placebo-controlled trial. Lancet. 2015 Jul 25;386(9991):341-9. doi: 10.1016\/S0140-6736(15)60933-3. Epub 2015 May 19. PMID: 26003623.\r\n\r\n[23] Huang W, Xue P, Zong H, Zhang Y. Efficacy and safety of silodosin in the medical expulsion therapy for distal ureteral calculi: a systematic review and meta-analysis. Br J Clin Pharmacol. 2016;81(1):13-22. doi:10.1111\/bcp.12737. PMID: 26255996; PMCID: PMC4693578.\n\r\n[24] Hsu YP, Hsu CW, Bai CH, Cheng SW, Chen KC, Chen C. Silodosin versus tamsulosin for medical expulsive treatment of ureteral stones: A systematic review and meta-analysis. PLoS One. 2018;13(8):e0203035. doi:10.1371\/journal.pone.0203035. PMID: 30153301; PMCID: PMC6112672.\n\r\n[25] \u00d6zsoy M, Liatsikos E, Scheffbuch N, Kallidonis P. Comparison of silodosin to tamsulosin for medical expulsive treatment of ureteral stones: a systematic review and meta-analysis. Urolithiasis. 2016;44(6):491-497. doi:10.1007\/s00240-016-0872-y. PMID: 27021350; PMCID: PMC5063919.\n\r\n[26] Fauzan MI, Daryanto B, Budaya TN, Makkaraka MAG, Fakhri M, Rahman IA. Promising selective alpha-1 blocker silodosin as a new therapeutic strategy for premature ejaculation and analysis of its drug adverse effect: A systematic review and meta-analysis of randomized controlled trials. Arch Ital Urol Androl. 2024;96(4):12984. doi:10.4081\/aiua.2024.12984. PMID: 39692416.\n\r\n[27] Nickel JC, M\u00e9ndez-Probst CE, Whelan TF, Paterson RF, Razvi H. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. 2010 Oct;4(5):310-6. doi: 10.5489\/cuaj.10124. PMID: 20941312; PMCID: PMC2950766.","gt-clinical-context":"<p>Os alfabloqueadores s\u00e3o utilizados em diversos cen\u00e1rios cl\u00ednicos, principalmente no tratamento da hiperplasia prost\u00e1tica benigna (HPB) e da hipertens\u00e3o.\u207d\u2079\u207e\u207d\u00b9\u2070\u207e\u207d\u00b9\u2077\u207e Na HPB, os bloqueadores alfa-1 seletivos, como tansulosina, alfuzosina e silodosina, s\u00e3o considerados agentes de primeira linha. Eles atuam relaxando a musculatura lisa da pr\u00f3stata e do colo vesical, o que alivia os sintomas do trato urin\u00e1rio inferior (STUI), como dificuldade para urinar, jato fraco e noct\u00faria. O al\u00edvio sintom\u00e1tico costuma ser observado poucos dias ap\u00f3s o in\u00edcio da terapia.\u207d\u00b9\u2070\u207e A sele\u00e7\u00e3o de pacientes para HPB normalmente envolve homens com STUI moderados a graves que n\u00e3o apresentam contraindica\u00e7\u00f5es \u00e0 terapia com alfabloqueadores. Os resultados esperados incluem melhora das taxas de fluxo urin\u00e1rio e redu\u00e7\u00e3o dos escores de sintomas.<\/p>\r\n<p>Na hipertens\u00e3o, alfabloqueadores como doxazosina e prazosina s\u00e3o geralmente considerados agentes de segunda linha devido a poss\u00edveis efeitos adversos, como a hipotens\u00e3o ortost\u00e1tica.\u207d\u2079\u207e Eles s\u00e3o usados quando outros anti-hipertensivos s\u00e3o insuficientes ou contraindicados. Esses medicamentos reduzem a press\u00e3o arterial ao causar vasodilata\u00e7\u00e3o dos vasos sangu\u00edneos perif\u00e9ricos. A sele\u00e7\u00e3o de pacientes envolve a considera\u00e7\u00e3o cuidadosa dos fatores de risco cardiovascular e da possibilidade de sintomas ortost\u00e1ticos. Os resultados esperados s\u00e3o uma redu\u00e7\u00e3o da press\u00e3o arterial sist\u00eamica.<\/p>\r\n<p>Os alfabloqueadores n\u00e3o seletivos, fenoxibenzamina e fentolamina, s\u00e3o aprovados pela FDA para o manejo do feocromocitoma, um tumor raro da medula adrenal que secreta catecolaminas em excesso. Eles s\u00e3o usados no pr\u00e9-operat\u00f3rio e no intraoperat\u00f3rio para controlar crises hipertensivas.\u207d\u00b9\u207e\u207d\u00b2\u207e A fentolamina tamb\u00e9m tem usos off-label, incluindo o tratamento de complica\u00e7\u00f5es cardiovasculares induzidas por coca\u00edna e como componente da terapia de inje\u00e7\u00e3o intracavernosa (Trimix) para a disfun\u00e7\u00e3o er\u00e9til masculina.\u207d\u00b3\u207e\u207d\u2074\u207e\u207d\u2075\u207e\u207d\u2076\u207e\u207d\u2077\u207e\u207d\u2078\u207e<\/p>\r\n<p>Os alfabloqueadores, particularmente os antagonistas alfa-1 seletivos como silodosina e tansulosina, tamb\u00e9m s\u00e3o empregados como terapia expulsiva medicamentosa (TEM) de primeira linha para c\u00e1lculos ureterais (pedras nos rins), especialmente os localizados no ureter distal. Eles relaxam a musculatura lisa ureteral, facilitando a elimina\u00e7\u00e3o espont\u00e2nea dos c\u00e1lculos.\u207d\u00b9\u2079\u207e\u207d\u00b2\u2070\u207e\u207d\u00b2\u00b9\u207e\u207d\u00b2\u00b2\u207e\u207d\u00b2\u00b3\u207e\u207d\u00b2\u2074\u207e\u207d\u00b2\u2075\u207e A terapia normalmente \u00e9 mantida por at\u00e9 tr\u00eas semanas. Bloqueadores alfa-1 seletivos, como a silodosina (off-label), tamb\u00e9m demonstraram alguma efic\u00e1cia no tratamento da ejacula\u00e7\u00e3o precoce, embora possam reduzir o volume do s\u00eamen.\u207d\u00b2\u2076\u207e Al\u00e9m disso, a terapia com alfabloqueadores (por exemplo, tansulosina off-label) pode ser considerada para pacientes do sexo feminino com STUI.\u207d\u00b9\u2078\u207e<\/p>\r\n<p>Procedimentos cir\u00fargicos n\u00e3o est\u00e3o diretamente associados \u00e0 administra\u00e7\u00e3o dos alfabloqueadores em si, mas esses medicamentos frequentemente fazem parte da estrat\u00e9gia de tratamento cl\u00ednico de condi\u00e7\u00f5es que podem, eventualmente, exigir cirurgia (por exemplo, HPB que progride a ponto de exigir ressec\u00e7\u00e3o transuretral da pr\u00f3stata se a terapia medicamentosa falhar ou for insuficiente). No contexto do feocromocitoma, o alfabloqueio \u00e9 parte fundamental do preparo perioperat\u00f3rio para a remo\u00e7\u00e3o cir\u00fargica do tumor.\u207d\u00b9\u207e\u207d\u00b2\u207e<\/p>","gt-related-evidence":null,"gt-featured":false,"gt-ai-referenced":false,"gt-view-count":256},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.7 (Yoast SEO v28.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon<\/title>\n<meta name=\"description\" content=\"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon\" \/>\n<meta property=\"og:description\" content=\"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/\" \/>\n<meta property=\"og:site_name\" content=\"Rigicon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/rigiconurology\/\" \/>\n<meta property=\"article:modified_time\" content=\"2026-10-06T20:21:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rigicon.com\/wp-content\/uploads\/2025\/05\/header-d.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"718\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon\" \/>\n<meta name=\"twitter:description\" content=\"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.\" \/>\n<meta name=\"twitter:site\" content=\"@rigiconurology\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/\",\"name\":\"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#website\"},\"datePublished\":\"2025-05-14T13:26:42+00:00\",\"dateModified\":\"2026-10-06T20:21:24+00:00\",\"description\":\"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/glossary-term\\\/bloqueadores-alfa-pt-br\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glossary Terms\",\"item\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/urology-glossary\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Bloqueadores Alfa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#website\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\",\"name\":\"Rigicon\",\"description\":\"Innovative Urological Solutions\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#organization\"},\"alternateName\":\"Innovative Urological Solutions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#organization\",\"name\":\"Rigicon, Inc.\",\"alternateName\":\"Innovative Urological Solutions\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"width\":512,\"height\":512,\"caption\":\"Rigicon, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/pt-br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/x.com\\\/rigiconurology\",\"https:\\\/\\\/www.instagram.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@Rigicon\\\/podcasts\",\"https:\\\/\\\/www.youtube.com\\\/Rigicon\",\"https:\\\/\\\/www.threads.com\\\/@rigiconurology\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/rigicon\\\/\",\"https:\\\/\\\/www.wikidata.org\\\/wiki\\\/Q141595822\"],\"description\":\"A Rigicon \u00e9 uma fabricante especializada, sediada nos EUA, de dispositivos de urologia prot\u00e9tica: pr\u00f3teses penianas, esf\u00edncteres urin\u00e1rios artificiais e pr\u00f3teses testiculares, comercializados em mais de 75 pa\u00edses.\",\"email\":\"operations@rigicon.com\",\"telephone\":\"+1 (888) 202-9790\",\"legalName\":\"Rigicon, Inc.\",\"vatID\":\"81-3545645\",\"taxID\":\"81-3545645\",\"duns\":\"045247683\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon","description":"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","og_locale":"pt_BR","og_type":"article","og_title":"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon","og_description":"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.","og_url":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","og_site_name":"Rigicon","article_publisher":"https:\/\/www.facebook.com\/rigiconurology\/","article_modified_time":"2026-10-06T20:21:24+00:00","og_image":[{"width":1440,"height":718,"url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2025\/05\/header-d.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_title":"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon","twitter_description":"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.","twitter_site":"@rigiconurology","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","url":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/","name":"Bloqueadores Alfa na Urologia: Indica\u00e7\u00f5es e Uso | Rigicon","isPartOf":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#website"},"datePublished":"2025-05-14T13:26:42+00:00","dateModified":"2026-10-06T20:21:24+00:00","description":"Saiba sobre os bloqueadores alfa na urologia: tratamento de HPB, sintomas do trato urin\u00e1rio inferior e c\u00e1lculos ureterais. Medicamentos e efeitos.","breadcrumb":{"@id":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.rigicon.com\/pt-br\/glossary-term\/bloqueadores-alfa-pt-br\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/www.rigicon.com\/pt-br\/"},{"@type":"ListItem","position":2,"name":"Glossary Terms","item":"https:\/\/www.rigicon.com\/pt-br\/urology-glossary\/"},{"@type":"ListItem","position":3,"name":"Bloqueadores Alfa"}]},{"@type":"WebSite","@id":"https:\/\/www.rigicon.com\/pt-br\/#website","url":"https:\/\/www.rigicon.com\/pt-br\/","name":"Rigicon","description":"Innovative Urological Solutions","publisher":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#organization"},"alternateName":"Innovative Urological Solutions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rigicon.com\/pt-br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/www.rigicon.com\/pt-br\/#organization","name":"Rigicon, Inc.","alternateName":"Innovative Urological Solutions","url":"https:\/\/www.rigicon.com\/pt-br\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/www.rigicon.com\/pt-br\/#\/schema\/logo\/image\/","url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","contentUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","width":512,"height":512,"caption":"Rigicon, Inc."},"image":{"@id":"https:\/\/www.rigicon.com\/pt-br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/rigiconurology\/","https:\/\/x.com\/rigiconurology","https:\/\/www.instagram.com\/rigiconurology\/","https:\/\/www.youtube.com\/@Rigicon\/podcasts","https:\/\/www.youtube.com\/Rigicon","https:\/\/www.threads.com\/@rigiconurology","https:\/\/www.linkedin.com\/company\/rigicon\/","https:\/\/www.wikidata.org\/wiki\/Q141595822"],"description":"A Rigicon \u00e9 uma fabricante especializada, sediada nos EUA, de dispositivos de urologia prot\u00e9tica: pr\u00f3teses penianas, esf\u00edncteres urin\u00e1rios artificiais e pr\u00f3teses testiculares, comercializados em mais de 75 pa\u00edses.","email":"operations@rigicon.com","telephone":"+1 (888) 202-9790","legalName":"Rigicon, Inc.","vatID":"81-3545645","taxID":"81-3545645","duns":"045247683"}]}},"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-term\/12471","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-term"}],"about":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/types\/glossary-term"}],"wp:attachment":[{"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/media?parent=12471"}],"wp:term":[{"taxonomy":"glossary-category","embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-category?post=12471"},{"taxonomy":"glossary-product","embeddable":true,"href":"https:\/\/www.rigicon.com\/pt-br\/wp-json\/wp\/v2\/glossary-product?post=12471"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}